From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
This article was originally published in The Pink Sheet Daily
Executive Summary
WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services.
You may also be interested in...
Novira Receives $23 Million To Develop New Antivirals
Previously supported by angels and seed-stage investors, the Philadelphia-area start-up has turned to 5AM Ventures and Canaan Partners for a Series A round that will support development of HBV and HIV drug candidates.
From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
SHANGHAI - 3SBio Inc.'s success with a biosimilar of Amgen Inc.'s erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government
Takeda Goes Virtual, Splitting Non-oncology Development Between Covance And Quintiles
TOKYO - Takeda Pharmaceuticals has teamed with contract research organizations Covance and Quintiles to move toward a "fully virtual outsourcing model," the company announced Feb. 15